» Articles » PMID: 26853313

A Simple Approach to Predict the Stability of Phospholipid Vesicles to Nebulization Without Performing Aerosolization Studies

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2016 Feb 9
PMID 26853313
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Membrane extrusion was investigated for predicting the stability of soya phosphatidylcholine liposomes and surfactosomes (Tween 80-enriched liposomes) to nebulization. Formulations were prepared with or without cholesterol, and salbutamol sulfate (SBS) or beclometasone dipropionate (BDP) were incorporated as model hydrophilic or hydrophobic drugs respectively. Formulations were extruded through 5, 2, 1 and 0.4 μm polycarbonate membrane filters to study the influence of membrane pore size on drug retention by the vesicles. Surfactosomes were found to be very leaky to SBS, such that even without extrusion greater than 50% of the originally entrapped drug was lost; these losses were minimized by the inclusion of cholesterol. The smaller the membrane pore size, the greater the leakage of SBS; hence only around 10% were retained in cholesterol-free surfactosomes extruded through 0.4 μm filters. To study the influence of vesicle size on SBS retained entrapment, an excessive extrusion protocol was proposed (51 extrusion cycles through 1 μm filters) to compare the stability of freshly prepared vesicles (i.e. unextruded; median size approx. 4.5-6.5 μm) with those previously extruded through 1 μm pores. Cholesterol was essential for minimizing losses from liposomes, whilst for surfactosomes size reduction prior to extrusion was the only way to minimize SBS losses which reached up to 93.40% of the originally entrapped drug when no cholesterol was included. When extrusion was applied to BDP-loaded vesicles, greater proportions of the drug were retained in the vesicles compared to SBS. Even with extrusion through 0.4 μm, BDP retention was around 50-60% with little effect of formulation. Excessive extrusion showed BDP retention using small liposomes (1 μm) to be as high as 71-87%, compared to 50-66% for freshly prepared vesicles. The findings, based on extrusion, were compared to studies of vesicle stability to nebulization, published by a range of investigators. It was concluded that extrusion is a valid method for predicting the stability of liposomes to nebulization.

Citing Articles

Investigation of Factors Influencing the Effectiveness of Deformable Nanovesicles for Insulin Nebulization Inhalation.

Yu J, Meng Y, Wen Z, Jiang Y, Guo Y, Du S Pharmaceutics. 2024; 16(7).

PMID: 39065576 PMC: 11280345. DOI: 10.3390/pharmaceutics16070879.


Impact of dispersion media and carrier type on spray-dried proliposome powder formulations loaded with beclomethasone dipropionate for their pulmonary drug delivery via a next generation impactor.

Khan I, Al-Hasani A, Khan M, Khan A, -Alam F, Sadozai S PLoS One. 2023; 18(3):e0281860.

PMID: 36913325 PMC: 10010524. DOI: 10.1371/journal.pone.0281860.


Development and Optimisation of Inhalable EGCG Nano-Liposomes as a Potential Treatment for Pulmonary Arterial Hypertension by Implementation of the Design of Experiments Approach.

Haddad F, Mohammed N, Gopalan R, Ayoub Y, Nasim M, Assi K Pharmaceutics. 2023; 15(2).

PMID: 36839861 PMC: 9965461. DOI: 10.3390/pharmaceutics15020539.


A Facile and Novel Approach to Manufacture Paclitaxel-Loaded Proliposome Tablet Formulations of Micro or Nano Vesicles for Nebulization.

Khan I, Lau K, Bnyan R, Houacine C, Roberts M, Isreb A Pharm Res. 2020; 37(6):116.

PMID: 32488363 PMC: 7266847. DOI: 10.1007/s11095-020-02840-w.


Development of Injectable PEGylated Liposome Encapsulating Disulfiram for Colorectal Cancer Treatment.

Najlah M, Said Suliman A, Tolaymat I, Kurusamy S, Kannappan V, Elhissi A Pharmaceutics. 2019; 11(11).

PMID: 31739556 PMC: 6920821. DOI: 10.3390/pharmaceutics11110610.